← Leaderboards
Samon Ho
Molecular Express, Inc.
$6,899,830
Attributed
$6,899,830
Total exposure
4
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $5M · FY2012–24$5M$3.8M$2.5M$1.3M$0
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$6,899,830 · 4
By mechanism
N01$2,999,352 · 1
N44$1,999,866 · 1
R44$1,499,000 · 1
R43$401,612 · 1
Top collaborators
No co-investigators on record.
Most similar at Molecular Express, Inc.
Same institution · by research overlap
- Gary Fujii$24,455,077
- Gretchen Jimenez$600,000
- Thai Quoc Do$329,911
- Sam Ho$599,983
- Sam Onho$599,925
Others in their field
Top investigators on “Adjuvant”
- Lawrence Corey · Fred Hutchinson Cancer Center$377,142,999
- Norman Wolmark · Nsabp Foundation, Inc.$267,141,611
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$167,183,168
- David Heimbrook · Leidos Biomedical Research, Inc.$151,668,128
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$131,206,481
- Peter B. Gilbert · Fred Hutchinson Cancer Center$117,668,001
Research focus
AdjuvantAntigensEngineeringLiposomesAgonistVaccinesLipidsDesignImmunogenicImmune ResponseResearch Clinical TestingAntigen TargetingPeptidesProteinsSiteLeadChimeric ProteinsImmunologyMolecularImmunogenicityFormulationBaseCarbohydratesPathogen
Grant awards (6)
VESIVAX TLR7 FORMULA$2,999,352
N01 · FY2024 · AI · contact PI
Design and Engineering of VesiVax HIV Immunogen Formulations$1,999,866
N44 · FY2024 · AI · contact PI
The VesiVax® System: Vaccine Development Made Easy$736,747
R44 · FY2017 · AI · contact PI
The VesiVax® System: Vaccine Development Made Easy$762,253
R44 · FY2016 · AI · contact PI
Formulation of TLR 3, 7, and 8 Agonists in Conjugatable Adjuvant Lipid Vesicles$194,073
R43 · FY2013 · AI · contact PI
Formulation of TLR 3, 7, and 8 Agonists in Conjugatable Adjuvant Lipid Vesicles$207,539
R43 · FY2012 · AI · contact PI